Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.45 |
| ▸ | PIK3R2 | O00459 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 9/20 | 0.42 |
| ▸ | JAK1 | P23458 | 9/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18208683 | 1.00 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R2PDE4BHPGD | |
| SCHEMBL18209027 | 0.84 | IRAK4 (0.50) | HPGDJAK2JAK1TYK2JAK3 | |
| SCHEMBL18209030 | 0.84 | IRAK4 (0.50) | HPGDJAK2JAK1TYK2JAK3 | |
| SCHEMBL20138810 | 0.82 | GRM4 (0.44) | PDE4BHPGD | |
| SCHEMBL20138812 | 0.82 | GRM4 (0.44) | PDE4BHPGD | |
| SCHEMBL20143016 | 0.79 | HPGD (0.49) | PDE4BHPGDJAK2JAK1TYK2 | |
| SCHEMBL20143015 | 0.79 | HPGD (0.49) | PDE4BHPGDJAK2JAK1TYK2 | |
| SCHEMBL20143023 | 0.77 | CCNA2 (0.49) | PDE4BHPGD | |
| SCHEMBL20143024 | 0.77 | CCNA2 (0.49) | PDE4BHPGD | |
| SCHEMBL18208181 | 0.75 | EPHB3 (0.56) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | claimed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292107-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | PIK3CD 3578/4885PIK3CG 3800/4885PIK3R2 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.